EFFECTIVE AND BINDING AGREEMENT. GSK and OIG agree as follows: A. This CIA shall be binding on the successors, assigns, and transferees of GSK; B. This CIA shall become final and binding on the date the final signature is obtained on the CIA; C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA; GlaxoSmithKline LLC Corporate Integrity Agreement D. The undersigned GSK signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA. E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. GlaxoSmithKline LLC Corporate Integrity Agreement This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the CIA.
Appears in 3 contracts
Samples: Corporate Integrity Agreement, Corporate Integrity Agreement, Corporate Integrity Agreement
EFFECTIVE AND BINDING AGREEMENT. GSK Novartis Pharmaceuticals Corporation Corporate Integrity Agreement Novartis and OIG agree as follows:
A. This CIA shall be binding on the successors, assigns, and transferees of GSKNovartis;
B. This CIA shall become final and binding on the date the final signature is obtained on the CIA;
C. This CIA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this CIA; GlaxoSmithKline LLC Corporate Integrity Agreement;
D. The undersigned GSK Novartis signatories represent and warrant that they are authorized to execute this CIA. The undersigned OIG signatory represents that he is signing this CIA in his official capacity and that he is authorized to execute this CIA.
E. This CIA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable, binding signatures for purposes of this CIA. GlaxoSmithKline LLC Novartis Pharmaceuticals Corporation Corporate Integrity Agreement APPENDIX A INDEPENDENT REVIEW ORGANIZATION This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E III.D of the CIA.
Appears in 1 contract
Samples: Corporate Integrity Agreement